EXAMINE THIS REPORT ON PADCEV PEMBROLIZUMAB

Keytruda can be a brand (trade) name for pembrolizumab. It can be given by intravenous infusion every 3 to 6 weeks. Rarely, using Keytruda results in the immune system attacking wholesome tissues and this can cause severe side effects including pneumonitis, colitis, or hepatitis. In a number of people, the usage of Keytruda has resulted inside the